22nd Century Group Inc Dossier - Source-backed chat

22nd Century Group Inc

XXIINASDAQ

SectorConsumer Staples

IndustryTobacco

Beta (adjusted)1.35

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.84Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $186.1K

Enterprise Value −$7M

Shares Outstanding 714K diluted

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

22nd Century Group, Inc. (NASDAQ: XXII) is a tobacco products company focused on harm reduction through its proprietary reduced nicotine technology (VLN®). While the company has achieved notable regulatory milestones as the only provider of FDA-authorized very low nicotine combustible cigarettes, its financial profile is critically weak. The company faces severe going-concern risks, persistent operating losses, negative gross margins, and a rapidly shrinking top line. Despite sequential revenue improvements and capital restructuring efforts (including a 1-for-20 reverse stock split in June 2026), the business remains highly speculative and unprofitable, with a cumulative deficit exceeding $402 million. Consequently, a Sell recommendation is warranted due to the high risk of equity dilution and ongoing operational instability.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company fails to achieve commercial traction for its Pinnacle platform, and contract manufacturing volumes continue to decline. Severe cash burn exhausts remaining liquidity, and the company is unable to raise additional capital, leading to insolvency or delisting from NASDAQ.

Base CaseCentral scenario

The company continues to expand its retail footprint toward its target of 5,000+ outlets by the end of 2026, supported by the launch of Pinnacle Pure and expansion into California. However, high SG&A and marketing expenses offset revenue gains, keeping the company unprofitable with persistent cash burn. Ongoing reliance on dilutive equity financing or warrant inducements remains necessary to sustain operations.

Bull CaseUpside scenario

The bull case for 22nd Century Group centers on its transition into a pure-play tobacco harm reduction company, leveraging its unique FDA Modified Risk Tobacco Product (MRTP) authorization for VLN® reduced-nicotine cigarettes (containing 95% less nicotine than traditional cigarettes). Following a comprehensive operational restructuring that eliminated long-term debt, the company is executing a high-margin commercial re-launch of its proprietary Pinnacle VLN® brand, targeting expansion to over 5,000 retail outlets by the end of 2026. Additionally, the company is pursuing high-margin licensing opportunities for its patented low-nicotine technology and expanding its PMTA portfolio to introduce new formats like 100mm cigarettes and filtered cigars, positioning it to capture market share as regulatory standards shift toward lower nicotine limits.

Scenarios reflect our research view at the research date.

Key Investment Merits

First and only FDA-authorized modified risk tobacco product (MRTP) combustible cigarette (VLN®).
Expanding retail footprint with a target of over 5,000 outlets by the end of 2026.
Launch of high-margin Pinnacle Pure platform to improve overall portfolio economics.

Key Investment Risks

Explicit going-concern warning due to persistent operating losses and a cumulative deficit of $402.2 million.
Negative gross margins and high cash burn from operations ($3.1 million in Q1 2026).
Severe risk of equity dilution from frequent capital restructuring, reverse stock splits, and warrant issuances.

Thesis Invalidation Triggers

Formal implementation of a low nicotine standard by the FDA, mandating minimally addictive levels in all combustible cigarettes.
Securing a major global licensing or distribution partnership that provides non-dilutive upfront capital.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.